- Advertise
- Contact Us
- Editorial Info
- Terms and Conditions
- Privacy Policy
- Do Not Sell My Personal Information
© 2022 MJH Life Sciences™ and Practical Cardiology. All rights reserved.
All News
Understanding Aficamten and the SEQUOIA-HCM Design, with Martin Maron, MD
October 05, 2022
Martin Maron, MD, sits down to discuss aficamten, the SEQUOIA-HCM trial, and the most pressing unmet needs in the management of hypertrophic cardiomyopathy.
8-in-10 Medicare Beneficiares Hospitalized with HFpEF Could be Considered Candidates for Dapagliflozin
October 04, 2022
An analysis applying data from the DELIVER trial to the Get With The Guidelines-Heart Failure Registry suggests 81% of hospitalized Medicare beneficiaries with HFpEF could be considered candidates for dapagliflozin use under a potential FDA label expansion.
Dapagliflozin's Benefit in HFpEF Reaches Significance Within 2 Weeks, Study Finds
October 03, 2022
A prespecified analysis of the DELIVER trial presented at HFSA 2022 indicates dapagliflozin provides early benefit in patients with heart failure with preserved ejection fraction, with the effect on the trial's primary end point evident in just 13 days.
Sacubitril/Valsartan Use Could Reduce Mitral Regurgitation in HFrEF
October 03, 2022
An analysis of data from the PROVE-HF trial suggests use of sacubitril/valsartan was associated with a reduction in prevalence of mitral regurgitation among patients with heart failure with reduced ejection fraction.
Aficamten Could Improve Quality of Life, Symptom Burden in Hypertrophic Cardiomyopathy
October 02, 2022
Data presented at HFSA 2022 examining aficamten provides insight into the effects of the agent on LVOT-G, NYHA class, and KCCQ-OSS among patients with hypertrophic cardiomyopathy from the open-label extension trial.
Optimizing Initiation of GDMT for Heart Failure, with Stephen Greene, MD
October 02, 2022
After a presentation on cost considerations and outcomes at HFSA 2022, Stephen Greene, MD, provides perspective on the current state of optimization for GDMT in heart failure.
Sotagliflozin Reduces Risk of Recurrent Heart Failure Events
October 02, 2022
New sotagliflozin data at HFSA 2022 provides insight into the apparent reduction in recurrent heart failure events achieved in the SOLOIST-WHF trial. Deepak Bhatt, MD, MPH, provides perspective on the potential role of the dual SGLT1/2 inhibitor, based on trial data, if approved by the US Food and Drug Administration.
Rates of Sudden Cardiac Death in Hypertrophic Cardiomyopathy Falling in Recent Years
October 01, 2022
Martin Maron, MD, provides perspective on a recent study he led examining changes in rate of sudden cardiac death among patients with hypertrophic cardiomyopathy and reflects on the progress made within disease management.
Don't Miss a Beat: HFSA 2022
October 01, 2022
In this special edition episode of Don’t Miss a Beat, which was filmed on-site at the HFSA 2022 annual scientific meeting, hosts Muthiah Vaduganathan, MD, MPH, codirector of Center for Cardiometabolic Implementation Science at Brigham and Women's Hospital, and Stephen Greene, MD, assistant professor of medicine at Duke University School of Medicine, take the audience on a deep dive into implementation science at the meeting, the potential for a polypill in heart failure, and other highlights from HFSA 2022.
No Excess Risk of Kidney Injury for ARNI Initiation in RASi Naive Patients
October 01, 2022
A comparison of data from Medicare Beneficiaries provides insight into the potential for risk of acute kidney injury with use of sacubitril/valsartan among patients who are RASi naive.